
Portal Biotechnologies
Portal Biotechnologies provides a mechanical cell-engineering platform for biopharma and academic research.
- Company
- Arlington, MA, USUnited States

Portal Biotechnologies provides a mechanical cell-engineering platform for biopharma and academic research.
portal.bioCrawled Oct 15, 2026
Consumables for virtually any cell type and cargo application
Read Portal articles on mechanoporation, circular RNA delivery, live-cell assays, high-throughput screening and cell engineering workflows.
Portal delivers circular RNA and tracer cargo to neutrophils directly in whole blood without upstream cell isolation.
Portal mechanoporation delivers circular RNA to primary T cells for extended expression and multiplexed engineering without integration.
Portal mechanoporation delivers LgBiT protein into live cells for protein degradation, target engagement and phosphorylation assays.
The page covers Portal Biotechnologies news, funding announcements, partnerships, press releases and media coverage.
The Portal team is developing a universal cell engineering platform for research, drug discovery and accessible cell therapy workflows.
Portal mechanoporation supports cell engineering and drug discovery workflows through intracellular delivery across cells and cargoes.
Portal Biotechnologies, a Watertown, Massachusetts-based cell engineering and drug discovery platform, raises $9 million in an oversubscribed funding round led by NFX. IA Ventures, Pear VC, Undeterred Ventures, IKJ Capital, and TechU Ventures also participate.
Jun 2026FinSMEsNews article
Portal Biotechnologies announces an oversubscribed $9 million round led by NFX, an expanded DARPA contract, and more than 100 customers across top pharmaceutical and academic centers.
Jun 2026Business WireNews article
Portal Biotechnologies receives an $8 million DARPA contract to develop a portable, field-deployable device for engineering red blood cells. The device is intended to enable rapid, point-of-care cell therapy production and treatment.
Jun 2025Business WireNews article
Portal Biotechnologies achieves $1 million in annual revenue under CEO Armon Sharei, who previously founded SQZ Biotechnologies. The Boston-based startup secures a $7 million seed funding round to advance its technology platform. Sharei attributes rapid growth to early customer adoption and product development milestones.
Dec 2024Boston Business JournalNews article